Off-market insider buying at Liminal BioSciences (T:LMNL)

Thomvest Asset Management Inc., a 10% Holder, acquired 3,157,894 Common Shares on an indirect ownership basis for registered holder Structured Alpha LP at a price of $4.750USD through a prospectus or prospectus exempt offering on November 3rd, 2020. The insider also acquired 3,157,894 Warrants with an exercise price of $5.500 for five long years. This represents a $19,717,495 investment into the company's shares and an account share holdings change of 18.9%.

The stock trades in the Unites States under ticker LMNL.

Liminal BioSciences is in the Biotechnology & Medical Research Sub Industry Group under the Healthcare Sector.

Liminal BioSciences Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing treatments for patients suffering from diseases primarily related to fibrosis, including respiratory, liver and kidney diseases. The Company operates through two segments: Small Molecule Therapeutics Segment and Plasma-derived Therapeutics Segment. The Small Molecule Therapeutics Segment is a small-molecule drug development business. Its lead small molecule product candidate is fezagepras (PBI-4050). The Plasma-derived Therapeutics Segment includes its plasma-derived therapeutics platform, which enables the development of its pipeline of biopharmaceutical candidates. Its lead plasma-derived product candidate is Ryplazim (plasminogen).